Intermittent Urethral Catheterization
Conditions
Brief summary
This is a prospective, double-blinded, randomized, multi-centre, cross-over study. All subjects will use both the study device (test catheter) and the comparator (control catheter) for one week each.
Interventions
DEVICETreatment Period One
LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
DEVICETreatment Period Two
CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
Sponsors
Wellspect HealthCare
Dentsply International
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provision of informed consent. * Males, aged 18 years and over. * Maintained urethra sensibility as judged by the subject. (Can you feel the catheter during catheterization? Yes.). * Practice CIC at least 2 times daily. * Using catheters in the size CH 12 or CH 14, Nelaton tip, and able to use catheter length of 40 cm. * Experienced users of CIC defined as a minimum of three months on therapy. * Adults able to read, write and understand information given to them regarding the study.
Exclusion criteria
* Ongoing, symptomatic UTI at enrolment as judged by investigator. The definition of UTI, is a positive urine culture of ≥103 CFU/ml of ≥1 bacterial species and presence of symptoms or signs compatible with UTI with no other identified source of infection. * Known urethral stricture which, in the opinion of the investigator, could influence the subject's evaluation of the catheters. * Involvement in the planning and conduct of the study (applies to both WHC staff and staff at the study site). * Previous enrolment or randomisation of treatment in the present study. * Simultaneous participation in another clinical study that may impact the primary endpoint. * Severe non-compliance to protocol as judged by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tolerability of practicing CIC by using two urinary catheters produced with different coating processes measuring change over time by means of subjective assessment scales | 2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two | The primary objective of this study is to compare the subjects' tolerability of practising CIC by using two urinary catheters produced with different coating processes by means of subjective assessment scales. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tolerability with regards to presence of bleeding, when using two different urinary catheters; test vs control catheter | 2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two. Safety variables spontaneously reported during whole study period | AE/SAE/ADE/SADE reporting /PRO variables. Assessed in patient questionnaire for each subject. A 5 graded scale will be used to determine the perception and the severity of each variable. The difference between the treatments will be calculated for each subject. |
| Tolerability with regards to perceived other discomfort, when using two different urinary catheters; test vs. control catheter | 2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two. Safety variables spontaneously reported during whole study period | PRO variables. Frequency of other discomfort (yes/ no) will be assessed in patient questionnaire. The frequency of other discomfort will be compared between the treatments. Other discomfort will be further specified using 5 graded scale (as for the other variables on the 5 graded scale the difference between the treatments will be calculated for each subject). |
| Tolerability with regards to perceived pain, when using two different urinary catheters; test vs control catheter. | 2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two. Safety variables spontaneously reported during whole study period | AE/SAE/ADE/SADE reporting/PRO variables. Assessed in patient questionnaire for each subject. A 5 graded scale will be used to determine the perception and the severity of each variable. The difference between the treatments will be calculated for each subject. |
| To evaluate subject satisfaction with catheter; test vs. control catheter. | 2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two. Safety variables spontaneously reported during whole study period | PRO variables. Assessed in patient questionnaire for each subject. A 5 graded scale will be used to determine the satisfaction. The difference between the treatments will be calculated for each subject. |
| Total number of DD/AE/SAE/ADE/SADE/ USADE. | 2 weeks in total. | Total number of DD/AE/SAE/ADE/SADE/ USADE observed by the study personnel or spontaneously reported from subject will be calculated. The frequency of DD/AE/SAE/ADE/SADE/ USADE will be calculated for each treatment group. |
| Perception of the catheter's slipperiness, smoothness, flexibility, usability, and resistance, when practicing intermittent self-catheterization with urinary catheters; test vs. control catheter | 2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two. Safety variables spontaneously reported during whole study period | PRO variables. Assessed in patient questionnaire for each subject. A 5 graded scale will be used to determine the perception and the severity of each variable. The difference between the treatments will be calculated for each subject. |
Countries
Sweden
Outcome results
None listed